Materials and Methods
Mice. Male C57BL/6 mice, 6-8 wk old, were supplied by the Shizuoka Animal Center (Shizuoka, Japan).
Tumors. 203 glioma is a malignant glioma cell line originally induced by 20-methylcholantherene from the C57BL/6 strain . The tumor cells were maintained in a monolayer form in tissue culture with Dulbecco's modified MEM (Nissui, Japan) supplemented with 10% heat-inactivated FCS (Gibco Laboratories, Grand Island, NY) and antibiotics (penicillin G, 200 U/ml; streptomycin sulfate, 50 Kg/ml). Methylcholantherene-induced mastocytoma (P815), originating from DBA/2 mice, and Moloney leukemia virus-induced T celllymphoma (YAC-1), originating from A/Sn mice, were maintained in RPMI 1640 (Nissui, Japan) with 10% heatinactivated FCS and antibiotics .
Lymphokines. Human rIL-2 (TGP-3; 4.2 x 104 U/mg protein) was kindly supplied by Takeda Chemical Industry, Ltd ., Osaka, Japan.
rmIL-5 was the culture supernatant ofX63-Ag8 .653 myeloma cells transfected with mIL-5 complementary DNA (14, 15) . Culture supernatant (SN) (1,200 U/ml) was filtered and aliquots were stored at -70°C. Activity was determined by polyclonal IgM plaque-forming cell (PFC) assay using TRFresponding BCLI cells (16) . This culture SN contained no IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, or CSF (data not shown) . Control culture SN was collected from the original myeloma cell (X63-Ag8-653) . Generation ofLAK Cells. Spleens were removed aseptically and crushed with the hub of a syringe in RPMI 1640. Spleen cells were incubated with mIL-5 at a concentration of 2 x 106 cells/ml for 3 d in the presence of IL-2 in RPMI 1640 with 10% heat-inactivated FCS and antibiotics . The culture was performed in 5-ml wells of a 6-well plate (Corning Glass Works, Corning, NY) . The cells were harvested, washed twice, and used as effectors .
Cytotoxicity Assay. A 4-h "Cr release assay in round-bottomed microtiter plates (Corning Glass Works) was used to measure cytotoxicity. Target cells were labeled with 0.1 mCi S'Cr (Amershatn Corp., Arlington Heights, IL) for 60 min at 37°C. Effectors were coincubated with the targets at various E/T ratios for 4 h at 37°C in humidified air with 5%a C02 . The radioactive SNs were harvested and counted with a gamma counter. The cytotoxic activity was calculated from the average of triplicate cultures as: percent of cytolysis = 100x (experimental release-spontaneous release)/(maximum release-spontaneous release). Spontaneous release was determined by adding culture medium only to the target cells and maximum release was counted in detergent . All determinations in each experiment were performed in triplicate.
Results
The Effect of rIL-5 on the Induction ofLAK Cells. Freshly isolated spleen cells were incubated with IL-2, rIL-5, or a combination ofIL-2 and rIL-5. As shown in Discussion The present study demonstrates that mIL-5 enhances the LAK activity in the presence of IL-2, though mIL-5 alone can not induce killer activity (Fig . 1) . We also found that in vitro the cell numbers are greater from cultures containing IL-2 plus mIL-5 than those containing IL-2 alone (data not shown) . As mIL-5 induces the expression of IL-2-R on both splenic B cells and PNA+ thymocytes (12, 13) The Effect ofrIL-5 on the Induction ofLAK Activity Depends on the Concentration ofIL-2. IL-2 mediated LAK cell activity is also dependent on IL-5 concentration. To determine the optimal concentration of IL-2 or rIL-5 to obtain the maximum cytotoxic activity, double titration experiments were carried out. In Fig. 2 , these killer activities show dose dependency at IL-2 concentrations from 0.01 to 10 U/ml and at rIL-5 concentrations from 0.01 to 100 U/ml .
The Effects of Various Time Schedules ofAdministration ofIL-2 and rIL-5 on the Induction ofLAK Activity. As shown in Fig. 3 , rIL-5 alone did not show killer activity when IL-2 was not present from the onset of culture (Fig. 3,j and k) . If IL-2 was present from the onset of culture, however, rIL-5 enhanced LAK activity, even when added 24-48 h after culture initiation (Fig. 3, h and a) . Finally, the presence of IL-2 for the first 24 or 48 h and rIL-5 during the last 48 or 24 h, respectively, did not enhance LAK activity (Fig. 3, d and e). These results suggest that rIL-5 acts on the late stage of the LAK induction in the presence of IL-2. Effect of various time schedules of administration of rIL-5 and rIL-2 on LAK induction. C57BL/6 mouse splenocytes were cultured. rIL-5 (25 U/ml) or rIL-2 (1 U/ml) was present in the culture for limited periods as indicated. After 3 d, cytotoxic activities against YAC-1 and P815 were measured at an E/T ratio of 20:1 . All determinations in each experiment were performed in triplicate .
not induce killer activity, some mechanisms involving IL-5-R probably may augment IL-2 signal transduction pathways . mIL-5 may act on the late stage of LAK induction in the presence of IL-2. As shown in Fig. 3 , c, h, and i, if IL-2 is present from the onset of culture, mIL-5 enhances LAK activity, even when mIL-5 is added at the late stage ofculture. IfmIL-5 is present from the onset of culture, however, killer activity is not so enhanced, even when IL-2 is added at the late stage (Fig. 3, j and k) . Hence, it might be possible that IL-2 activates precursor cells in the first stage, and mIL-5 augments the activated precursor cells. Moreover, this effect cannot take place in the absence of IL-2 (Fig . 3, f and g ).
Mule et al. (17) found that mIL-4 alone induces killer activity as well as IL-2-mediated killer activity. mIL-5, on the other hand, enhances IL-2-mediated killer activity, but mIL-5 alone does not induce the killer activity. These results suggest that the mechanism by which LAK activity is augmented by mIL-5 is different from that of mIL-4.
Unlike IL-2, mIL-4 has little capacity to generate LAK activity from mouse PBL, whereas both lymphokines induce this activity from splenocytes (17) . Whether or not mIL-5 and IL-2 similarly generate LAK activity from mouse PBL remains to be determined.
Hergen et al. (18) found that human IL-4 blocks IL-2-generated LAK activity. The reason for the discrepancy between human and mouse IL-4 is unclear. Apart from the possibility that the ability of IL-4 to block the induction of LAK activity is species restricted, it might be possible that mouse spleen cells contain already acti- 
